June 22, 2009

Immunoproteasome Blocker as Weapon Against Arthritis

Feature story on the June 14 feature in 'Nature Medicine' in which scientists from Proteolix - whose proteasome inhibitor Carfilzomib is in climincal trials for several hematological cancers - and colleagues from the German University of Konstanz showed that the pre-clinical compound PR-957 might be useful to ameliorate rheumatoid arthritis.